Fisher Asset Management LLC Sells 53,245 Shares of Medpace Holdings, Inc. $MEDP

Fisher Asset Management LLC lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 29.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 125,347 shares of the company’s stock after selling 53,245 shares during the quarter. Fisher Asset Management LLC owned approximately 0.45% of Medpace worth $39,341,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Assetmark Inc. grew its position in Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after acquiring an additional 43 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Medpace by 2.3% during the first quarter. LPL Financial LLC now owns 18,374 shares of the company’s stock worth $5,469,000 after purchasing an additional 414 shares during the last quarter. Commerce Bank grew its holdings in shares of Medpace by 3.9% during the first quarter. Commerce Bank now owns 2,138 shares of the company’s stock worth $651,000 after purchasing an additional 80 shares during the last quarter. Roberts Glore & Co. Inc. IL increased its stake in shares of Medpace by 2.2% in the first quarter. Roberts Glore & Co. Inc. IL now owns 4,251 shares of the company’s stock valued at $1,295,000 after buying an additional 90 shares during the period. Finally, Ontario Teachers Pension Plan Board raised its holdings in Medpace by 86.6% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 14,208 shares of the company’s stock valued at $4,329,000 after buying an additional 6,592 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 59,025 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the transaction, the chief executive officer directly owned 774,602 shares in the company, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Jesse J. Geiger sold 21,503 shares of the firm’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 364,079 shares of company stock valued at $219,241,718 in the last ninety days. 20.30% of the stock is owned by corporate insiders.

Medpace Trading Down 0.7%

Shares of MEDP opened at $583.70 on Wednesday. The firm’s fifty day simple moving average is $564.15 and its two-hundred day simple moving average is $449.46. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26. The stock has a market capitalization of $16.44 billion, a P/E ratio of 40.82, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same period last year, the company posted $3.01 EPS. The business’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of several recent research reports. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. BMO Capital Markets started coverage on Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price for the company. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. Finally, Cowen reissued a “sell” rating on shares of Medpace in a research note on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $487.18.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.